Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.54 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.54 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | TNNC1 | P63316 | 5/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.45 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509404 | 1.00 | DPP4 (0.58) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL14168977 | 0.90 | RAB9A (0.51) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL295667 | 0.88 | DPP4 (0.62) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL27462751 | 0.88 | DPP4 (0.62) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL27529280 | 0.87 | DPP4 (0.61) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL3511410 | 0.87 | DPP4 (0.61) | DPP4NPC1RAB9ATDP1CASP3 | |
| Hydrochloric Acid SCHEMBL1820938 | 0.87 | DPP4 (0.61) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL5991627 | 0.87 | DPP4 (0.61) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL27553090 | 0.87 | DPP4 (0.61) | DPP4NPC1RAB9ATDP1CASP3 | |
| SCHEMBL7621778 | 0.86 | TNNC1 (0.56) | THRATHRBTNNC1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | claimed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | claimed |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | SANKYO COMPANY, LIMITED (JP) | 2007-06-28 | — | — | US | claimed |
| EP-1782804-A1 | MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | claimed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| EP-2045325-B1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO CO LTD (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100248227-A1 | DRUG-PHOSPHORYLATING ENZYME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2045325-A1 | DRUG-PHOSPHORYLATING ENZYME | Daiichi Sankyo Company, Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-06-26 | — | — | US | disclosed |
| EP-1915994-A1 | CYCLIC AMINE DERIVATIVE CONTAINING PPAR REGULATOR | Sankyo Company, Limited (JP) | 2008-04-30 | — | — | EP | disclosed |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | SANKYO COMPANY, LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1782804-A1 | MEDICINAL COMPOSITION AS IMMUNOSUPPRESSANT | Sankyo Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153882-A1 | Pharmaceutical Composition Comprising Ppar Regulator | PPARG, PPARA, PPARD | DPP4 3499/4885NPC1 3921/4885RAB9A 3907/4885 |
| US-20070149597-A1 | Medicinal composition as immunosuppressant | HMGCR, SHMT1, CYP11B1 | DPP4 4767/4885NPC1 469/4885RAB9A 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.